AI Article Synopsis
- Study investigates the impact of three single nucleotide polymorphisms (SNPs) in the CYP2C19 gene on susceptibility to high-altitude pulmonary edema (HAPE) among the Chinese Han population.
- 238 cases and 230 controls were analyzed for genetic associations using various statistical methods.
- The study found that the SNP rs4494250 in the CYP2C19 gene significantly increased HAPE risk in individuals over 32 years old, but was associated with decreased risk in those aged 2 years or younger.
Article Abstract
Introduction: High-altitude pulmonary edema (HAPE) is caused by the interaction of both genetic and environmental risk factors.
Objectives: In this study, we aimed to explore whether three single nucleotide polymorphisms (SNPs) in CYP2C19 gene influenced the HAPE susceptibility in the Chinese Han population.
Methods: We recruited 238 cases and 230 controls between January 2018 and October 2018 from the Affiliated Hospital of Xizang Minzu University. The relationship between CYP2C19 gene polymorphisms and HAPE was studied by association analysis. Genotyping was performed using the Agena MassARRAY platform and the statistical analysis was performed using Chi-squared test, independent sample t test, genetic model analysis and haplotype analysis.
Results: The main finding of our study showed that rs4494250 in CYP2C19 gene was associated with an increased risk of HAPE at age >32 years in the log-additive model (OR = 1.80, 95% CI = 1.05-3.09, P = 0.033). Also, it was observed to be associated with a reduced risk of HAPE at age ≤2 years in the dominant model (A/G-A/A vs G/G, OR = 0.55, 95% CI = 0.31-0.97, P = 0.038) and in the log-additive model (OR = 0.58, 95% CI = 0.35-0.96, P = 0.033).
Conclusion: Our findings demonstrated that CYP2C19 genetic variants were associated with risk of developing HAPE in Han Chinese population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/crj.13232 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis.
Clin Pract Epidemiol Ment Health
December 2024
Laboratory of Panic and Respiration, Instituto de Psiquiatria, Universidade Federal do Rio de Janeiro (UFRJ). Rio de Janeiro, RJ, Brazil.
Background: Many pharmacological treatments are considered effective in the treatment of panic disorder (PD), however, about 20 to 40% of the patients have treatment-resistant PD. Pharmacogenetics could explain why some patients are treatment-resistant.
Objective: Our objective was to gather preliminary data on the clinical usefulness of pharmacogenetic testing in this disorder.
Detecting CYP2C19 genes through an integrated CRISPR/Cas13a-assisted system.
Anal Methods
January 2025
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
CYP2C19 gene single nucleotide polymorphisms (SNPs) should be considered in the clinical use of clopidogrel as they have important guiding value for predicting the risk of bleeding and thrombosis after clopidogrel treatment. The CRISPR/Cas system is increasingly used for SNP detection owing to its single-nucleotide mismatch specificity. Simultaneous detection of multiple SNPs for rapid identification of the CYP2C19 genotype is important, but there is no method to detect a wide variety of CYP2C19 SNPs.
View Article and Find Full Text PDFValidating the accuracy of mathematical model-based pharmacogenomics dose prediction with real-world data.
Eur J Clin Pharmacol
January 2025
Electrical and Computer Engineering Department, School of Engineering, Lebanese American University, P.O. Box: 36, Byblos, F-19, Lebanon.
Objective: The study aims to verify the usage of mathematical modeling in predicting patients' medication doses in association with their genotypes versus real-world data.
Methods: The work relied on collecting, extracting, and using real-world data on dosing and patients' genotypes. Drug metabolizing enzymes, i.
Delineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.
Curr Drug Discov Technol
December 2024
Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamil Nadu, 603203, India
Background: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!